We are Main Street
U.S.

Haleon Strategy Boosted CVS Sales by 24% With GLP-1 Shelves

Consumer goods manufacturers are tailoring shelf placement to reach patients managing GLP-1 side effects.

Updated on Sept. 18, 2026 in Consumer Goods

Isometric editorial illustration of clean, geometric product bottles arranged in a repeating grid on a retail shelf display.
Haleon reported a 24% increase in sales at CVS stores in the first quarter of 2026, driven by a new retail shelf strategy for GLP-1 treatment side effects. AI Illustration. Upload story photo >

Live Poll

Do you trust national brand health products enough to pay more than store-brand equivalents?

Haleon has implemented a retail strategy to place products for side-effect management on dedicated GLP-1 destination shelves in CVS Pharmacy locations. This merchandising shift resulted in a 24% average sales increase per store during the first quarter of 2026.

Why it matters

The strategy allows manufacturers to turn the common side effects of GLP-1 weight-loss drugs—such as nausea and constipation—into a revenue driver for health product portfolios. With 11% of American adults now using these medications, the approach targets a growing patient demographic.

The retail strategy delivered a 24% sales lift per CVS store during the first quarter of 2026. This initiative supports a company with a market capitalization of approximately £29.67 billion as of September 17, 2026.

The players

Haleon

A global consumer healthcare company that manufactures over-the-counter brands including Advil, TUMS, and Sensodyne.

CVS Pharmacy

A major American retail pharmacy chain that manages health product assortments and provides clinical pharmacy services.

The details

Haleon, which manufactures brands like Advil, TUMS, and Sensodyne, is grouping products that treat nausea, vomiting, diarrhea, and dry mouth in dedicated retail displays. CVS has expanded this assortment to include both national and its own store brands alongside Haleon products. This creates a convenience-driven shopping environment for the 11% of American adults currently using GLP-1 drugs, directly addressing common treatment side effects at the point of sale.

Timeline

  1. 2022: Haleon completed its separation from GlaxoSmithKline.

  2. Q1 2026: Retail strategy delivered a 24% sales lift per CVS store.

  3. 2026: First-generation oral GLP-1 pills were launched.

  4. September 16, 2026: Haleon publicly revealed the retail strategy for GLP-1 products.

  5. September 17, 2026: Haleon shares traded at 337.40 GBX.

Market Landscape

The rise of GLP-1 weight-loss drug prescriptions is currently reshaping how retail pharmacy chains like CVS structure their over-the-counter aisles to capture new patient spending. Haleon is adapting to this trend by consolidating symptom-relief products into dedicated destination sets.

Operators in the health and consumer goods space should track how GLP-1 usage informs shelf-space allocation and inventory bundling. If the strategy expands to major retailers like Walmart and Target, it may set a new standard for how pharmacy departments manage category adjacencies.

The takeaway

Manufacturers should look for ways to align product lines with the clinical side-effect profiles of high-growth pharmaceutical trends. Monitor the success of store-brand alternatives in these destination shelves to gauge potential pressure on your own pricing power.

Further reading

For more on industry shifts in retail merchandising, see our coverage of Consumer Goods.

Source note: This article includes information reported by Idaho Statesman.

Live Poll

Do you trust national brand health products enough to pay more than store-brand equivalents?